Eligible patients will have newly-diagnosed Covid-19 and also have been identified with an increased risk of complications of infection due to age and comorbidities.
The study was designed in response to recent evidence suggesting that severe COVID-19 infections are associated with increased frequency of thrombosis.
Symptomatic patients with COVID-19 receiving the LMWH (via enoxaparin) will be compared with patients receiving the standard of care.
The follow up period for assessing outcomes including hospitalization and mortality is at 21 days, with further assessments at 50 days and 90 days.
Symptomatic COVID-19 patients receiving the LMWH (via enoxaparin) will be compared with patients receiving the standard of care.
The follow up period for assessing outcomes including hospitalization and mortality is at 21 days, with further assessments at 50 days and 90 days.
The study will be funded by an investigator-initiated study grant provided by Sanofi.
The Thrombosis Research Institute is in innovative solutions for the detection and treatment of thrombosis. Sanofi is a global biopharmaceutical company focused on improving human health.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business